Skip to content
Disclosery

Krensavage Asset Management, LLC

Follow

13F filer, CIK 1609251, NEW YORK, NY

Krensavage Asset Management, LLC reported $255,697,000 across 20 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 86.89% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001609251-26-000004

Period
2026-03-31
Reported value
$256M
Holdings
20
Top 10 weight
86.89%
New
5
Sold out
3

Largest buys vs the previous quarter

SecurityShares changeApprox. value
INDVnew+339,532$10.3M
EMBCnew+735,340$6.5M
RAREadded+241,245$5.05M
ARDXnew+500,000$3M
BIIBadded+10,000$1.83M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AVADEL PHARMACEUTICALSexited-855,860-$18.4M
CAHexited-73,745-$15.2M
INDIVIOR PLCexited-339,532-$12.2M
UTHRreduced-7,000-$4.15M
BNTXreduced-40,000-$3.55M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001609251-26-000004, largest first. % of portfolio is the value over $255,697,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 100,332 shares; 2024Q4: 92,057 shares; 2025Q1: 98,228 shares; 2025Q2: 101,146 shares; 2025Q3: 97,646 shares; 2025Q4: 91,282 shares; 2026Q1: 84,282 shares 84,282$50M19.55%-7,000Timeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,498,074 shares; 2024Q4: 2,117,390 shares; 2025Q1: 2,116,586 shares; 2025Q2: 2,114,444 shares; 2025Q3: 2,114,444 shares; 2025Q4: 2,766,390 shares; 2026Q1: 2,866,138 shares 2,866,138$36.2M14.16%+99,748Timeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 110,257 shares; 2024Q4: 105,803 shares; 2025Q1: 100,703 shares; 2025Q2: 164,816 shares; 2025Q3: 167,816 shares; 2025Q4: 167,816 shares; 2026Q1: 167,816 shares 167,816$31.7M12.41%0Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 405,450 shares; 2025Q4: 524,786 shares; 2026Q1: 524,786 shares 524,786$29.6M11.59%0Timeline
EXELEXELIXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,281,612 shares; 2024Q4: 965,866 shares; 2025Q1: 878,533 shares; 2025Q2: 493,526 shares; 2025Q3: 518,526 shares; 2025Q4: 493,526 shares; 2026Q1: 415,693 shares 415,693$17.8M6.97%-77,833Timeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 150,205 shares; 2024Q4: 149,196 shares; 2025Q1: 149,096 shares; 2025Q2: 148,946 shares; 2025Q3: 323,946 shares; 2025Q4: 323,946 shares; 2026Q1: 323,946 shares 323,946$15.6M6.1%0Timeline
SUPNSUPERNUS PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 431,986 shares; 2025Q2: 472,376 shares; 2025Q3: 363,479 shares; 2025Q4: 313,499 shares; 2026Q1: 280,681 shares 280,681$14.5M5.67%-32,818Timeline
INDVINDIVIOR PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 339,532 shares 339,532$10.3M4.05%newTimeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 149,634 shares; 2026Q1: 390,879 shares 390,879$8.19M3.2%+241,245Timeline
VNDAVANDA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 414,684 shares; 2024Q4: 378,762 shares; 2025Q1: 754,381 shares; 2025Q2: 1,024,883 shares; 2025Q3: 1,180,388 shares; 2025Q4: 1,180,388 shares; 2026Q1: 1,180,388 shares 1,180,388$8.16M3.19%0Timeline
EMBCEMBECTA CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 735,340 shares 735,340$6.5M2.54%newTimeline
GSKGSK PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 272,000 shares; 2025Q2: 271,729 shares; 2025Q3: 271,729 shares; 2025Q4: 96,729 shares; 2026Q1: 96,729 shares 96,729$5.34M2.09%0Timeline
BNTXBIONTECH SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 93,583 shares; 2024Q4: 88,663 shares; 2025Q1: 87,563 shares; 2025Q2: 73,382 shares; 2025Q3: 79,366 shares; 2025Q4: 99,523 shares; 2026Q1: 59,523 shares 59,523$5.29M2.07%-40,000Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 251,495 shares; 2024Q4: 238,136 shares; 2025Q1: 207,822 shares; 2025Q2: 207,822 shares; 2025Q3: 207,822 shares; 2025Q4: 107,822 shares; 2026Q1: 107,822 shares 107,822$3.81M1.49%0Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 113,502 shares; 2024Q4: 108,923 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 20,000 shares 20,000$3.67M1.43%+10,000Timeline
REGNREGENERON PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 353 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 4,000 shares; 2025Q3: 4,000 shares; 2025Q4: 4,000 shares; 2026Q1: 4,000 shares 4,000$3.09M1.21%0Timeline
ARDXARDELYX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares 500,000$3M1.17%newTimeline
INMDINMODE LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 120,942 shares 120,942$1.65M0.65%newTimeline
EOLSEVOLUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 157,985 shares 157,985$649K0.25%+57,985Timeline
ABTABBOTT LABORATORIESQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,000 shares 5,000$513K0.2%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
AVADEL PHARMACEUTICALSAVADEL PHARMACEUTICALS855,860$18.4Mshares
CAHCARDINAL HEALTH INC73,745$15.2Mshares
INDIVIOR PLCINDIVIOR PLC339,532$12.2Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001609251-26-000004 base2026-05-15acceptance time not in the bulk data set